Abstract 1611P
Background
Living with brain metastasis (BM) causes distress for patients and family carers. Patients report a wide range of physical, social and psychological problems that affect daily life for them and their families. Despite the high prevalence of BM, little is known about the experiences of family carers. This qualitative study explores how family carers of BM patients perceive the information and communication about diagnosis, the health care services provided, and how their lives are affected by the BM.
Methods
This was a prospective qualitative study with individual semi-structured interviews. Participants were interviewed three times; shortly after the BM diagnosis, and then after two and four months. A total of 40 interviews with 18 adult family carers (13 spouses, 2 adult children, 2 siblings) were conducted. Transcripts were analysed using a reflexive thematic analysis. A trajectory matrix was developed for the longitudinal design, searching for overarching themes over time as well as changes in the themes identified.
Results
For many family carers the BM diagnosis was experienced as particularly frightening, given that the metastases were located in the brain. Family carers felt that they lived in a rapidly changing, chaotic and unpredictable situation. They reported working nonstop to coordinate family life, the patient’s health care follow-up, and to maintain a sort of normality in daily life. The situation affected their relationship with the patient, especially daily life activities and communication. The need for information was extensive among most family carers. They emphasized a need for more information about treatment and prognosis to be able to plan for the future. This information need remained high through all interviews.
Conclusions
Being a family carer of a patient with BM implies extensive practical, emotional and psychosocial challenges. The need for continuous information is particularly high, and health care providers should tailor their information to the individual recipient. Palliative care, with a person-centred approach and systematic follow up of the needs of family carers, should be introduced in an early stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
The Norwegian Cancer Society Pink Ribbon and The Norwegian South-East Health Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05